The data for these analyses were made available to the authors by third-party license from IBM MarketScan®, a commercial data provider in the US, and Janssen Pharmaceuticals (who have a license for analysis of the IBM MarketScan® Commercial and Medicare Supplemental data). As such, the authors cannot provide the raw data themselves. Other researchers could access the data by purchase through IBM MarketScan®; and the inclusion criteria specified in the Methods section would allow them to identify the same cohort of patients we used for these analyses. Interested individuals may visit ibm.com/watsonhealth for more information on accessing IBM MarketScan® Commercial and Medicare Supplemental data. We confirm that no authors had special privileges to access data from IBM MarketScan® via third-party license, and that other researchers would be able to access the data in the same manner as the authors.

Introduction {#sec005}
============

Major depressive disorder (MDD) is a common chronic mental disorder with 6.7% of American adults estimated to have had at least one MDD episode in 2016 \[[@pone.0220763.ref001]\]. It is characterized by depressed mood, persistent sadness, suicidal ideation, and frequent healthcare resource utilization. Globally, MDD is the second leading cause of disability, and it ranks second within the United States \[[@pone.0220763.ref002]\]. The economic burden of MDD in the U.S. is substantial; it was estimated to be greater than \$200 billion in 2010, with 45% attributable to direct costs \[[@pone.0220763.ref003]\].

There are several pharmacologic and non-pharmacologic treatment options for patients with MDD; however, the episodic and sometimes refractory nature of MDD makes treatment difficult to manage and costly. Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) trial showed that approximately one-third of patients with MDD have persistent symptoms despite receiving multiple treatments \[[@pone.0220763.ref004]\]. Although no consensus definition exists for treatment-resistant depression (TRD), the Agency for Healthcare Research and Quality (AHRQ) defines TRD as when a patient with MDD does not respond or remit after at least 2 trials of antidepressant (AD) treatment regimens of adequate dosage and duration, a definition consistent with Food and Drug Administration (FDA) guidance \[[@pone.0220763.ref005],[@pone.0220763.ref006]\].

MDD is associated with increased physical impairment and poor quality of life. Patients with TRD generally experience greater symptom severity \[[@pone.0220763.ref007]\], more comorbid conditions \[[@pone.0220763.ref008],[@pone.0220763.ref009]\], poorer quality of life \[[@pone.0220763.ref010],[@pone.0220763.ref011]\], and higher risk of suicide \[[@pone.0220763.ref012]\] compared to those with non-TRD MDD. Furthermore, healthcare resource use and costs of MDD are more extensive among those with TRD \[[@pone.0220763.ref009],[@pone.0220763.ref011]--[@pone.0220763.ref015]\]. At the rates of 12--20% of patients with depression, TRD is estimated to have an added annual cost ranging between \$29 billion and \$48 billion in the U.S. that yields higher total societal healthcare costs than those of non-TRD MDD \[[@pone.0220763.ref011]\].

The substantial clinical and economic burdens of MDD emphasize the need for better management, especially in the case of TRD. However, the characteristics of MDD and TRD have not been well studied at the level of treatment episodes in the real-world setting. Furthermore, the treatment patterns of MDD episodes, as well as the sequential transition through lines of therapy (LOT), are not well described. Therefore, the objectives of this study were to characterize MDD and TRD at the level of pharmacologically treated episodes and describe the sequential patterns of AD treatment, with and without an antipsychotic (AP), by LOT.

Methods {#sec006}
=======

Data source {#sec007}
-----------

This analysis represents an episode-level retrospective cohort study that utilized claims data extracted from the IBM MarketScan Commercial and Medicare Supplemental databases. The Commercial database contains pharmacy and medical (inpatient and outpatient) claims of employees and their dependents; the Medicare Supplemental database profiles the health care experience of individuals with Medicare supplemental insurance. Both databases provide detailed outcomes measures, including resource utilization and associated costs for individuals covered annually by a geographically diverse group of self-insured employers and private insurance plans across the US. The patient data from the MarketScan databases are de-identified and thus in compliance with the Health Insurance Portability and Accountability Act (HIPAA).

Patient selection {#sec008}
-----------------

Adults ≥18 years of age with at least one MDD diagnosis (International Classification of Diseases \[ICD\]-9 codes: 296.2, 296.3; ICD-10 codes: F32.0---F32.5, F32.9, F33.0---F33.4, F33.9) and prescription fill of an AD, with or without a MDD-indicated antipsychotic (aripiprazole, brexpiprazole, olanzapine or quetiapine), were identified between January 1, 2010 and December 31, 2015. The date of the first MDD diagnosis was designated as the index date. All patients were required to have had continuous insurance enrollment ≥12 months prior to the index date and ≥12 months after the index date. Patients were excluded if they were diagnosed with the psychiatric comorbidities of psychosis, schizophrenia, bipolar disorder, dementia and Tourette syndrome any time during the study period. Patients included in the study were required to have ≥1 completed MDD episode during the study period, as defined below.

Study design {#sec009}
------------

This episode-level analysis examined only pharmacologically treated MDD episodes, which were those when a patient had a diagnosis for MDD and a prescription fill for any AD with or without one of the MDD-indicated APs. As illustrated in [Fig 1](#pone.0220763.g001){ref-type="fig"}, the 1^st^ MDD episode began at the date of the first observed MDD diagnosis and was required to be preceded by a 365-day "clean period" without any MDD diagnosis or AD/AP prescription fill. A completed MDD episode was defined by ≥180 days without an MDD diagnosis or an AD/AP claim, with the episode end date assigned as the date of the last MDD diagnosis or the end of the days' supply of AD/AP medication, whichever came last. A subsequent MDD episode started on the date of another MDD diagnosis that was preceded by a ≥180-day clean period, and the MDD diagnosis had to be accompanied by ≥1 AD/AP prescription fill during the episode. TRD was defined as an MDD episode with ≥3 AD/AP regimens, in which a regimen was defined as any combination of AD/AP used with a continuous segment of ≥28 days' supply (allowing a maximum 60-day gap). The regimen may have included AD polypharmacy or augmentation with a MDD-indicated AP. LOTs were defined as the sequence patterns of treatment regimens within each episode.

![Study design.\
AD: antidepressant; LOT: line of therapy; MDD: major depressive disorder; TRD: treatment-resistant depression.](pone.0220763.g001){#pone.0220763.g001}

Study measures {#sec010}
--------------

Episode duration in number of days, the number of AD/AP LOT, and proportions of episodes involving a relapse hospitalization were evaluated for the 1^st^ and 2^nd^ treated MDD episodes, stratified by TRD and non-TRD episodes. Relapse was defined as a hospitalization with a primary diagnosis of MDD or suicidal ideation. For the 1^st^ treated MDD episode, patterns of AD/AP treatment regimens, as well as the treatment sequences from the first LOT (LOT1) to second LOT (LOT2) and from LOT2 to the third LOT (LOT3), were evaluated. The top 20 commonly observed treatment sequence patterns (LOT1 to LOT3) during the 1^st^ treated TRD episode were also reported. Treatment sequence patterns were described at the drug class level (i.e., selective serotonin reuptake inhibitors \[SSRIs\], serotonin and norepinephrine reuptake inhibitors \[SNRIs\], bupropion, serotonin modulators \[nefazodone, trazodone, vilazodone and vortioxetine\], tetracyclics, tricyclics, SSRIs + AP, and other combinations). All AD/AP included in this study were captured via General Product Identifier (GPI) codes from pharmacy claims and the Healthcare Common Procedure Coding System (HCPCS) codes from medical claims. The remission duration between 1^st^ and 2^nd^ treated MDD episodes was additionally determined and stratified by TRD and non-TRD episodes. Patient demographics included age, gender, geographic region, insurance type, and health plan type and were reported separately for those with 1^st^ treated MDD episodes and those with 2^nd^ treated MDD episodes.

Statistical analyses {#sec011}
--------------------

Descriptive statistics were utilized to describe patient demographics and measured outcomes. Mean and standard deviation (SD) were reported for continuous variables; percentages were reported for categorical variables. All statistical analyses were conducted using SAS Enterprise Guide 7 (SAS Institute Inc., Cary NC).

Results {#sec012}
=======

Study population {#sec013}
----------------

Patient attrition is shown in [Fig 2](#pone.0220763.g002){ref-type="fig"}. Of the 98,809 patients with ≥1 completed MDD episode during the study period, 49% (N = 48,440) were pharmacologically treated in the 1^st^ MDD episode. The mean age of patients with the 1^st^ treated MDD episode was 39.2 (SD: 15.4) years, 61.6% were female, and the majority had commercial insurance (94.9%) ([S1 Table](#pone.0220763.s001){ref-type="supplementary-material"}). Of the patients with ≥1 treated MDD episode, 3.5% (N = 1,739) had a 2^nd^ treated MDD episode ([S1 Table](#pone.0220763.s001){ref-type="supplementary-material"}) during the observed follow-up period. The mean age of patients with a 2^nd^ treated MDD episode was 38.6 (SD: 14.6) years and 67.3% were female ([S1 Table](#pone.0220763.s001){ref-type="supplementary-material"}).

![Attrition diagram.\
\*Psychosis, schizophrenia, bipolar disorder, dementia and Tourette syndrome. MDD: major depressive disorder.](pone.0220763.g002){#pone.0220763.g002}

Characteristics of 1^st^ and 2^nd^ treated MDD episodes {#sec014}
-------------------------------------------------------

The characteristics of the 1^st^ and 2^nd^ treated MDD episodes are shown in [Fig 3](#pone.0220763.g003){ref-type="fig"}. The mean duration of 1^st^ treated MDD episodes was 226 (SD: 225) days, the mean number of AD/AP LOTs was 1.36 (SD: 0.73), and 9.9% involved relapse hospitalization during the episode. Of the 1^st^ MDD episodes, 6.8% (N = 3,317) of episodes were qualified as TRD. The mean duration of 1^st^ TRD episodes was 571 (SD: 285) days, the mean number of AD/AP LOTs was 3.47 (SD: 0.84), and 13.7% involved relapse hospitalization. The mean duration of 1^st^ non-TRD episodes was 200 (SD: 198) days, the mean number of AD/AP LOTs was 1.21 (SD: 0.42), and 9.6% involved relapse hospitalization.

![Characteristics of 1^st^ and 2^nd^ treated MDD episodes.\
LOT: line of therapy; MDD: major depressive disorder; TRD: treatment-resistant depression.](pone.0220763.g003){#pone.0220763.g003}

The mean duration of 2^nd^ treated MDD was 183 (SD: 174) days, the mean number of AD/AP LOTs was 1.29 (SD: 0.64), and 7.8% involved relapse hospitalization during the episode. Of the 2^nd^ MDD episodes, 5.3% (N = 93) were considered as TRD. The mean duration of 2^nd^ TRD episodes was 482 (SD: 220) days, the mean number of AD/AP LOT was 3.37 (SD: 0.70), and 12.9% involved relapse hospitalization. The mean duration of 2^nd^ non-TRD MDD episodes was 166 (SD: 154) days, the mean number of AD/AP LOTs was 1.17 (SD: 0.39), and 7.5% involved relapse hospitalization.

The average remission time between 1^st^ and 2^nd^ treated MDD episodes was 403 (SD: 225) days; the average remission time for TRD episodes was shorter than that of non-TRD MDD episodes (330 \[SD: 163\] days vs. 407 \[SD: 227\] days). Among 1^st^ treated MDD episodes, the rate of recurrence was small. Among those with at least one-year follow-up after exiting a treatment episode, 4.3% had a subsequent treated episode. Among those with at least two-years follow-up, 7.2% had a subsequent treated episode.

AD/AP treatment regimens during the 1^st^ treated MDD episode {#sec015}
-------------------------------------------------------------

Patterns of AD/AP treatment during the 1^st^ treated MDD episode are shown in [Fig 4](#pone.0220763.g004){ref-type="fig"}. Among 1^st^ treated MDD episodes (N = 48,440), 25.5% (N = 12,330) included a LOT2, and 7.3% (N = 3,549) included a LOT3. For LOT1, SSRI monotherapy was the predominant regimen (63.0%). Other AD regimens were used at a much lower frequency (bupropion: 10.5%; other SSRIs-containing combo: 7.1%; SNRIs: 6.8%). In LOT2 and LOT3, the plurality of regimens remained SSRI monotherapy (44.9% and 41.1%, respectively).

![Patterns of antidepressant/antipsychotic treatment during the 1st treated MDD episode.\
AP: antipsychotic; Combo: combination; LOT: line of therapy; MDD: major depressive disorder Misc: miscellaneous; SNRIs: serotonin norepinephrine reuptake inhibitors; SSRIs: selective serotonin reuptake inhibitors.](pone.0220763.g004){#pone.0220763.g004}

Treatment sequence patterns during the 1^st^ treated MDD episode {#sec016}
----------------------------------------------------------------

Tables [1](#pone.0220763.t001){ref-type="table"} and [2](#pone.0220763.t002){ref-type="table"} show the treatment sequence patterns from LOT1 to LOT2 and from LOT2 to LOT3, respectively, during the 1^st^ treated MDD episode. Of the LOT1 treated with SSRIs, 24.6% (N = 7,519) involved a sequence to a LOT2, of which most remained on SSRI monotherapy (58.2%). For LOT1 treated with other AD/AP drug classes and drug combinations, the frequency of having a LOT2 was lowest with tricyclics (20.9%) and highest with SSRI + AP (34.4%). Generally, three regimens were disproportionately represented at LOT2: 1) SSRI monotherapy (left most column in Tables [1](#pone.0220763.t001){ref-type="table"} and [2](#pone.0220763.t002){ref-type="table"}), [2](#pone.0220763.t002){ref-type="table"}) the same drug class used in LOT1 (diagonal cells in Tables [1](#pone.0220763.t001){ref-type="table"} and [2](#pone.0220763.t002){ref-type="table"}), or 3) Other SSRI-containing Combo (the 10^th^ regimen column in Tables [1](#pone.0220763.t001){ref-type="table"} and [2](#pone.0220763.t002){ref-type="table"}). Among LOT2 with a treatment sequence to LOT3, similar treatment patterns were observed as for LOT1 to LOT2.

10.1371/journal.pone.0220763.t001

###### Treatment sequence patterns from LOT1 to LOT2 during the 1^st^ treated MDD episode.

![](pone.0220763.t001){#pone.0220763.t001g}

  LOT 1 Regimen Distribution       Began LOT 2   LOT 1 --- \> LOT 2 Matrix                                                                                                                                                                  
  -------------------------------- ------------- --------------------------- ------------ ------- ----------- ----------- ----------- --------- --------- --------- --------- --------- --------- ----------- --------- --------- --------- ------------
  **Antidepressant Class**         N             \%                          n            \%                                                                                                                                                
  **SSRIs**                        30,507        63.0%                       7,519        24.6%   58.2%       6.4%        7.6%        2.8%      1.1%      1.6%      7.2%      2.5%      0.2%      10.6%       0.5%      0.4%      0.9%      **100%**
  **SNRIs**                        3,313         6.8%                        846          25.5%   20.6%       39.4%       7.9%        5.1%      0.5%      2.7%      0.7%      0.7%      4.8%      5.9%        9.6%      0.5%      1.7%      **100%**
  **BPN**                          5,100         10.5%                       1,264        24.8%   22.0%       5.6%        35.9%       2.6%      1.1%      2.0%      16.5%     0.2%      0.1%      2.3%        2.4%      8.6%      0.6%      **100%**
  **S Mod**                        1,435         3.0%                        362          25.2%   25.4%       6.1%        3.9%        31.2%     1.9%      3.6%      0.8%      0.6%      3.3%      14.1%       0.0%      5.0%      4.1%      **100%**
  **Tetracyclics**                 1,091         2.3%                        254          23.3%   20.9%       3.9%        5.1%        5.5%      28.0%     2.4%      0.0%      0.0%      1.2%      14.2%       2.8%      6.7%      9.4%      **100%**
  **Tricyclics**                   722           1.5%                        151          20.9%   21.9%       6.0%        3.3%        7.3%      2.0%      39.7%     1.3%      0.0%      0.0%      7.3%        2.0%      2.6%      6.6%      **100%**
  **SSRI + BPN**                   706           1.5%                        212          30.0%   32.5%       9.9%        7.1%        3.3%      1.9%      2.8%      14.2%     1.9%      0.0%      14.6%       2.4%      5.7%      3.8%      **100%**
  **SSRs + AP**                    483           1.0%                        166          34.4%   22.9%       2.4%        3.0%        2.4%      2.4%      0.6%      3.6%      17.5%     0.0%      28.3%       5.4%      2.4%      9.0%      **100%**
  **SSRI + S Mod**                 234           0.5%                        75           32.1%   16.0%       17.3%       4.0%        12.0%     2.7%      4.0%      0.0%      0.0%      10.7%     12.0%       13.3%     2.7%      5.3%      **100%**
  **Other SSRI-containing Comb**   3,457         7.1%                        1,067        30.9%   30.5%       4.2%        8.6%        7.3%      1.7%      2.6%      3.8%      3.8%      2.2%      26.0%       3.2%      2.3%      3.7%      **100%**
  **Other SNRI-containing Comb**   322           0.7%                        103          32.0%   14.6%       12.6%       8.7%        3.9%      0.0%      1.9%      3.9%      1.0%      7.8%      9.7%        22.3%     8.7%      4.9%      **100%**
  **Other BPN-containing Comb**    509           1.1%                        156          30.6%   19.9%       5.8%        13.5%       7.7%      0.6%      1.3%      6.4%      2.6%      1.9%      12.8%       5.1%      18.6%     3.8%      **100%**
  **Other Misc. Comb**             561           1.2%                        155          27.6%   21.9%       5.2%        4.5%        7.1%      2.6%      2.6%      0.0%      16.1%     1.3%      7.1%        4.5%      2.6%      24.5%     **100%**
  **Grand Total**                  **48,440**    **100.0%**                  **12,330**           **5,533**   **1,037**   **1,273**   **553**   **218**   **297**   **849**   **302**   **117**   **1,377**   **251**   **268**   **255**   **12,330**

AP: antipsychotic; BPN: bupropion; Comb: combination; LOT: line of therapy; Misc: miscellaneous; S Mod: serotonin modulator; SNRI: serotonin norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor

10.1371/journal.pone.0220763.t002

###### Treatment sequence patterns from LOT2 to LOT3 during the 1^st^ treated MDD episode.

![](pone.0220763.t002){#pone.0220763.t002g}

  LOT 2 Regimen Distribution        Begin LOT 3   LOT 2 --- \> LOT 3 Matrix                                                                                                                                                      
  --------------------------------- ------------- --------------------------- ----------- ------- ----------- --------- --------- --------- -------- -------- --------- -------- -------- --------- --------- -------- --------- -----------
  **SSRIs**                         5,533         44.9%                       1,460       26.4%   65.1%       5.5%      5.8%      3.4%      0.7%     1.4%     6.4%      1.7%     0.1%     8.6%      0.4%      0.2%     0.7%      **100%**
  **SNRIs**                         1,037         8.4%                        290         28.0%   17.2%       42.4%     9.7%      4.5%      0.3%     3.1%     1.4%      0.0%     4.8%     2.8%      11.7%     0.3%     1.7%      **100%**
  **BPN**                           1,273         10.3%                       351         27.6%   19.9%       6.8%      42.2%     2.6%      1.1%     1.1%     12.0%     0.3%     0.3%     1.7%      3.4%      8.0%     0.6%      **100%**
  **S Mod**                         553           4.5%                        157         28.4%   17.2%       5.1%      8.9%      33.8%     3.8%     2.5%     0.6%      0.6%     4.5%     12.1%     0.0%      3.8%     7.0%      **100%**
  **Tetracyclics**                  218           1.8%                        65          29.8%   12.3%       7.7%      1.5%      1.5%      41.5%    9.2%     0.0%      0.0%     0.0%     13.8%     1.5%      4.6%     6.2%      **100%**
  **Tricyclics**                    297           2.4%                        85          28.6%   24.7%       4.7%      7.1%      10.6%     2.4%     30.6%    0.0%      0.0%     0.0%     16.5%     2.4%      0.0%     1.2%      **100%**
  **SSRI + BPN**                    849           6.9%                        279         32.9%   28.3%       9.0%      8.6%      2.9%      0.4%     0.7%     22.2%     2.9%     0.7%     15.8%     3.9%      3.6%     1.1%      **100%**
  **SSRI + AP**                     302           2.4%                        108         35.8%   16.7%       6.5%      4.6%      5.6%      0.0%     0.9%     3.7%      22.2%    0.9%     22.2%     5.6%      1.9%     9.3%      **100%**
  **SSRI + S Mod**                  117           0.9%                        38          32.5%   18.4%       10.5%     5.3%      10.5%     0.0%     2.6%     0.0%      0.0%     15.8%    7.9%      21.1%     2.6%     5.3%      **100%**
  **Other SSRI-containing Comb**    1,377         11.2%                       450         32.7%   28.4%       8.0%      4.9%      7.8%      1.6%     2.9%     4.9%      4.2%     1.6%     23.3%     4.2%      3.1%     5.1%      **100%**
  **Other SNRIs-containing Comb**   251           2.0%                        85          33.9%   20.0%       8.2%      5.9%      4.7%      1.2%     0.0%     3.5%      1.2%     3.5%     7.1%      32.9%     5.9%     5.9%      **100%**
  **Other BPN-containing Comb**     268           2.2%                        92          34.3%   10.9%       6.5%      23.9%     3.3%      1.1%     2.2%     4.3%      1.1%     3.3%     13.0%     5.4%      20.7%    4.3%      **100%**
  **Other Misc. Comb**              255           2.1%                        89          34.9%   21.3%       7.9%      6.7%      2.2%      2.2%     3.4%     0.0%      9.0%     0.0%     9.0%      9.0%      6.7%     22.5%     **100%**
  **Grand Total**                   **12,330**    **97.9%**                   **3,549**           **1,404**   **337**   **368**   **196**   **62**   **91**   **236**   **88**   **45**   **384**   **140**   **98**   **100**   **3,549**

AP: antipsychotic; BPN: bupropion; Comb: combination; LOT: line of therapy; Misc: miscellaneous; S Mod: serotonin modulator; SNRI: serotonin norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor

Most common treatment patterns (LOT1 to LOT3) for 1^st^ TRD episodes {#sec017}
--------------------------------------------------------------------

The 20 most commonly observed treatment sequence patterns, which comprised 1,743 (52.5%) of the total 3,317 TRD episodes, are shown in [Table 3](#pone.0220763.t003){ref-type="table"}. By far the most frequently observed treatment pattern of 1^st^ TRD episodes was multiple SSRIs in different LOTs, with 23.9% treated with SSRIs in LOT1, LOT2, and LOT3. All other treatment patterns were present in \<5% of patients.

10.1371/journal.pone.0220763.t003

###### Top 20 treatment patterns (LOT 1 to LOT 3) for 1^st^ treated TRD episodes.

![](pone.0220763.t003){#pone.0220763.t003g}

                                                                                                         N           \%
  ------------------------------------------------------------------------------------------------------ ----------- -----------
      SSRIs---\> SSRIs---\> SSRIs                                                                        792         23.9%
      SSRIs---\> Other SSRIs-containing Combo---\> SSRIs                                                 81          2.4%
      SSRIs---\> SSRIs---\> Other SSRIs-containing Combo                                                 79          2.4%
      Bupropion---\> Bupropion---\> Bupropion                                                            78          2.4%
      SSRIs---\> SSRIs---\> SSRIs + Bupropion                                                            70          2.1%
      SSRIs---\> SSRIs---\> Bupropion                                                                    66          2.0%
      SSRIs---\> SSRIs---\> SNRIs                                                                        62          1.9%
      SNRIs---\> SNRIs---\> SNRIs                                                                        56          1.7%
      Other SSRIs-containing Combo---\> SSRIs---\> SSRIs                                                 51          1.5%
      SSRIs---\> SSRIs + Bupropion---\> SSRIs                                                            49          1.5%
      SSRIs---\> Bupropion---\> SSRIs                                                                    48          1.4%
      SSRIs---\> Other SSRIs-containing Combo---\> Other SSRIs-containing Combo                          44          1.3%
      SSRIs---\> SNRIs---\> SNRIs                                                                        42          1.3%
      SSRIs---\> Bupropion---\> Bupropion                                                                39          1.2%
      Bupropion---\> SSRIs---\> SSRIs                                                                    37          1.1%
      SSRIs---\> SNRIs---\> SSRIs                                                                        33          1.0%
      SSRIs---\> SSRIs---\> Serotonin Modulators                                                         31          0.9%
      SSRIs---\> SSRIs + Bupropion---\> SSRIs + Bupropion                                                31          0.9%
      Other SSRIs-containing Combo---\> Other SSRIs-containing Combo---\> Other SSRIs-containing Combo   29          0.9%
      SSRIs---\> Bupropion---\> SSRIs + Bupropion                                                        25          0.8%
  **TRD episodes comprising 20 most common treatment patterns**                                          **1,743**   **52.5%**

Combo: combination; LOT: line of therapy; SNRIs: serotonin norepinephrine reuptake inhibitors; SSRIs: selective serotonin reuptake inhibitors

Discussion {#sec018}
==========

In recent years there has been considerable attention given to TRD in the published literature. However, information on MDD and TRD at the episode level is lacking with respect to the number and types of AD/AP regimens used as well as the sequential pattern of LOT transitioning. A notable finding of our study was that less than half of MDD patients were pharmacologically treated; and the MDD episodes in general were lengthy, lasting over 220 days. In addition, TRD episodes were nearly three times longer than non-TRD MDD episodes for both 1^st^ and 2^nd^ treated episodes. Despite pharmacologic treatment, 10% of MDD episodes involved a relapse resulting in hospitalization. Despite use of an average 3.5 LOTs during 1^st^ TRD episodes, TRD episodes were associated with more relapse hospitalizations than non-TRD MDD episodes. The durations of MDD/TRD episodes, number of relapse hospitalizations, and frequency of changing LOTs observed in this study highlight the significant unmet need for alternative novel and/or supplemental treatment options to the conventional spectrum of ADs used for the management of MDD and TRD.

Approximately two-thirds of 1^st^ treated MDD episodes observed in this study were treated with SSRIs during LOT1. SSRIs remained the most common treatment used in LOT2 and LOT3 during the 1^st^ MDD and TRD episodes. Moreover, many patients with TRD cycled within the SSRI class. This preference for SSRIs may be reflective of clinician or patient familiarity, affordability, or the perception that all classes of oral antidepressants offer similar efficacy, but SSRIs offer better tolerability compared with other classes. These findings suggest a need for new antidepressants with improved efficacy for patients with TRD. Adjunctive APs do offer incremental efficacy compared with continued oral antidepressant monotherapy. Nevertheless, APs were used infrequently in the 1^st^ MDD episode, and the highest fraction of patients receiving SSRIs + AP in LOT1 transitioned to LOT2. These two findings may reflect the tolerability burden of adjunctive AP. When interpreting these results, it is important to recognize that starting and stopping the same medication after the requisite gap counts as a new LOT.

The recurrence rate of MDD episodes could not be explicitly determined in this study. Due the variable length follow-up, it was not possible to interpret the number of 2^nd^ treated MDD episodes compared with the number of 1^st^ treated MDD episodes as a rate of progression, since patients may not have had long enough follow-up time to detect a 2^nd^ episode. Nevertheless, we observed that among those who completed an episode with sufficient post-episode follow-up, the recurrence risk was low and appeared to decline over time. That is, the longer a patient remained out of a treatment episode the lower the chance of episode recurrence. This relatively low percentage should be interpreted in the context of the 180-day clean period that was used in this study. Although further study is needed, these results suggest that patients who achieve episode remission for 6 months have a good prognosis; this could become an important clinical goal. Given that the MDD episodes are typically long in duration, it is critical that patients receive better and perhaps more intensive treatment and care management because MDD, and especially TRD, are clinically debilitating and worsened dramatically by the increased likelihood for suicide. In a recent study, Bauer et al conducted an analysis of large-scale clinical trials, and concluded that algorithm-guided treatment for MDD, in which systematic assessment of treatment response is performed at critical decision points, provides a structured mechanism that is associated with improved treatment outcomes versus usual treatment \[[@pone.0220763.ref016]\]. Alongside the refractory nature of MDD, especially TRD, findings from this study emphasize the significant need for more widespread use of improved treatment strategies for patients diagnosed with MDD.

Due to the nature of claims database studies, we were not able to directly assess other clinical measures of treatment responsiveness (e.g., diminution of symptoms) of patients with MDD. Instead proxy measures (e.g., prescription fills, subsequent MDD diagnoses) were used to indirectly detect treatment responsiveness and changes in treatment. For this analysis of patients newly diagnosed with MDD, we used a restrictive 365-day pre-index "clean period" during which no MDD diagnosis or prescription fill for AD/AP was identified. Additionally, we required patients to have a ≥180-day clean period between MDD episodes to define a completed episode and entry into remission. These design aspects, while restrictive, were rigorous and conservative in the identification of potential treatment non-response. However, they might have contributed to a TRD prevalence estimate that is lower than that reported in previous studies \[[@pone.0220763.ref013],[@pone.0220763.ref014]\].

This was an episode-level retrospective cohort study that utilized claims data extracted from the MarketScan databases. It has limitations that should be recognized when interpreting these results. Among these are that administrative claims data are collected for facilitating payment for healthcare services and not for research. When claims data are used to identify diagnoses, results may be incomplete or inaccurate, leading to potential misclassification bias. Also, generic prescriptions paid out-of-pocket may not be captured in claims databases. This may have led to an underestimate of both drug utilization and MDD episode duration. Claims for prescription fills may not necessarily be reflective of the actual medication taken. This study utilized an empirical clean period length and maximum permissible gap, which may have impacted the identification of MDD episodes and LOTs. Also, this study only included patients covered by commercial or Medicare supplemental insurance; therefore, the results may not be generalizable to other populations with other types of insurance coverage (i.e., Medicaid). By study design, only patients with completed treatment episodes were included in the study population. Thus, these study results may not generalize well to patients who have extended treated MDD episodes.

Conclusions {#sec019}
===========

This study utilized an episodic approach for evaluating the treatment journey of patients with newly diagnosed MDD. The results suggest that, compared with non-TRD MDD episodes, TRD episodes are longer, more frequently involve relapse hospitalization and have shorter duration of remission. This study also reveals a real-world treatment pattern of AD during the treated MDD episode, in which the most common AD drug class used in sequential LOTs was the same one used in the initial LOT. Of potential AD treatment classes, an SSRI was the most frequently used treatment across LOTs. Findings from this study may help to better understand the disease burden of TRD and unmet treatment needs in the management of patients with MDD, especially those with TRD.
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###### Patient Demographics.

CDHP: consumer-driven health plan; HMO: health maintenance organization; MDD: major depressive disorder; POS: point-of-service plan; PPO: preferred provider organization.
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Click here for additional data file.
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